Portfolio Company Headlines


March 18, 2020

Austin, TX and Ames, IA
NewLink Genetics Stockholders Approve Merger with Lumos Pharma

February 25, 2020

Austin, TX
BioStable Science & Engineering Announces Initial Closing of Series C Equity Round

February 19, 2020

Austin, TX
Molecular Templates, Inc. Announces Dosing of First Subject in Phase I Study of TAK-169 in Relapsed/Refractory Multiple Myeloma

February 3, 2020

Plymouth Meeting, PA
Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial

November 21, 2019

Austin, TX
Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

November 18, 2019

Boston, MA and Austin, TX
Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

September 30, 2019

Austin, TX and Ames, IA
NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases

July 10, 2019

Plymouth Meeting, PA
Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

June 26, 2019

Austin, TX
Remedy Raises $10 Million to Bring Quality Care Closer to Patients

June 17, 2019

Austin, TX
Molecular Templates Announces FDA Acceptance of IND Application for TAK-169, An Engineered Toxin Body Targeting CD38

May 16, 2019

Menlo Park, CA
FARAPULSE featured prominently at 2019 HRS Scientific Sessions

May 8, 2019

Menlo Park, CA
FARAPULSE Receives FDA Breakthrough Designation for its Endocardial Pulsed Field Ablation System

May 3, 2019

Austin, TX
BioStable Science & Engineering Surpasses 500 Patients Treated Worldwide with the HAART Devices

April 23, 2019

San Carlos, CA
BAROnova Announces FDA Approval of the TransPyloric Shuttle® (TPS®) Device

February 21, 2019

Plymouth Meeting, PA
Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies